Pharmacogenetics and Breast Cancer Endocrine Therapy: CYP2D6 as a Predictive Factor for Tamoxifen Metabolism and Drug Response?

Expert Reviews in Molecular Medicine - United Kingdom
doi 10.1017/s1462399408000896
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Cambridge University Press (CUP)

Related search

The Relationship Between the CYP2D6 Polymorphisms and Tamoxifen Efficacy in Adjuvant Endocrine Therapy of Breast Cancer Patients in Chinese Han Population

International Journal of Cancer
Cancer ResearchOncology
2018English

Hormone Receptor-Negative as a Predictive Factor for Pathologic Complete Response to Neoadjuvant Therapy in Breast Cancer

Einstein (São Paulo, Brazil)
Medicine
2019English

Prevalent Breast Cancer Patients With a Homozygous Mutant Status for CYP2D6*4: Response and Biomarkers in Tamoxifen Users

Breast Cancer Research and Treatment
Cancer ResearchOncology
2009English

The Emerging Role of ESR1 Mutations in Luminal Breast Cancer as a Prognostic and Predictive Biomarker of Response to Endocrine Therapy

Cancers
Cancer ResearchOncology
2019English

Predicting Response/Resistance to Endocrine Therapy for Breast Cancer

Breast Cancer Research
Cancer ResearchOncology
2005English

Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated With Tamoxifen

Frontiers in Pharmacology
Pharmacology
2017English

Composite Functional Genetic and Comedication CYP2D6 Activity Score in Predicting Tamoxifen Drug Exposure Among Breast Cancer Patients

Journal of Clinical Pharmacology
Pharmacology
2010English

Selective Recruitment of Breast Cancer Anti-Estrogen Resistance Genes and Relevance for Breast Cancer Progression and Tamoxifen Therapy Response

Endocrine-Related Cancer
Cancer ResearchEndocrinologyOncologyMetabolismDiabetes
2010English

CYP2D6 Genotyping and Tamoxifen in the Treatment of Post-Menopausal Breast Cancer - A Reply

British Journal of Clinical Pharmacology
Pharmacology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy